Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Jul 14, 3:26PM CDT

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.4400 (+1.41%)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer GlobeNewswire - Mon Jul 13, 7:00AM CDT

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4400 (+1.41%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Jun 18, 3:01PM CDT

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options...

GERN : 1.4400 (+1.41%)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire - Mon Jun 1, 7:00AM CDT

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4400 (+1.41%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets FinancialNewsMedia - Wed May 20, 8:45AM CDT

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1497 (+7.70%)
BIOA : 22.81 (+2.93%)
LCTX : 1.1600 (-0.85%)
GERN : 1.4400 (+1.41%)
FATE : 2.78 (+1.83%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon May 18, 3:01PM CDT

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options...

GERN : 1.4400 (+1.41%)
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026  GlobeNewswire - Tue May 12, 8:31AM CDT

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population  Additional presentations...

GERN : 1.4400 (+1.41%)
Geron: Q1 Earnings Snapshot AP - Wed May 6, 6:26AM CDT

Geron: Q1 Earnings Snapshot

GERN : 1.4400 (+1.41%)
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire - Wed May 6, 6:00AM CDT

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating...

GERN : 1.4400 (+1.41%)
Geron's First Commercial Quarter Tests Whether Rytelo Launch Momentum Holds Barchart - Tue May 5, 4:15PM CDT

Barchart Research What to Expect from GERN Earnings GERN Generated May 5, 2026 Current Price $1.6500 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 8.78% Geron's First Commercial Quarter...

GERN : 1.4400 (+1.41%)

Barchart Exclusives

Alphabet Is Up 94% and Meta Is Down 5%. Barchart Data Helps Pick the Best AI Dividend Stock to Buy Now. Barchart - Fri Jul 17, 6:00PM CDT
Alphabet’s broader ecosystem gives it the long-term edge, while Meta offers faster growth, a lower valuation and a higher yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.